Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03556228
Title Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors VM Oncology, LLC
Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.